EA200701826A1 - Способ и композиция для лечения диабета - Google Patents

Способ и композиция для лечения диабета

Info

Publication number
EA200701826A1
EA200701826A1 EA200701826A EA200701826A EA200701826A1 EA 200701826 A1 EA200701826 A1 EA 200701826A1 EA 200701826 A EA200701826 A EA 200701826A EA 200701826 A EA200701826 A EA 200701826A EA 200701826 A1 EA200701826 A1 EA 200701826A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
treating diabetes
cells
ihems
treating
Prior art date
Application number
EA200701826A
Other languages
English (en)
Inventor
Донни Рудд
Дэвид А. Вулф
Original Assignee
Редженетек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редженетек, Инк. filed Critical Редженетек, Инк.
Publication of EA200701826A1 publication Critical patent/EA200701826A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение направлено на ИВЭМС-размножение стволовых клеток крови млекопитающего, предпочтительно клеток CD34+/CD38-, композиции, полученные на основе ИВЭМС-размноженных клеток, и на способ лечения заболевания либо восстановления ткани с помощью упомянутых композиций.
EA200701826A 2005-02-28 2006-02-27 Способ и композиция для лечения диабета EA200701826A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65755305P 2005-02-28 2005-02-28
PCT/US2006/006817 WO2006093858A2 (en) 2005-02-28 2006-02-27 Method and composition for treating diabetes

Publications (1)

Publication Number Publication Date
EA200701826A1 true EA200701826A1 (ru) 2008-04-28

Family

ID=36941684

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701826A EA200701826A1 (ru) 2005-02-28 2006-02-27 Способ и композиция для лечения диабета

Country Status (11)

Country Link
US (1) US20060193838A1 (ru)
EP (1) EP1855535A4 (ru)
JP (1) JP2008531695A (ru)
KR (1) KR20070111533A (ru)
CN (1) CN101188941A (ru)
BR (1) BRPI0607882A2 (ru)
CA (1) CA2599275A1 (ru)
EA (1) EA200701826A1 (ru)
IL (1) IL185555A0 (ru)
MX (1) MX2007010531A (ru)
WO (1) WO2006093858A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2599274A1 (en) * 2005-02-28 2006-09-08 Regenetech, Inc. Method of providing readily available cellular material derived from peripheral blood and a composition thereof
US20070190520A1 (en) * 2006-02-02 2007-08-16 Wolf David A Method of characterizing a biologically active compound
US20090081752A1 (en) * 2007-09-24 2009-03-26 Dennis Robert G Bioreactor, kit and method of using same
US8993231B2 (en) * 2008-03-18 2015-03-31 Marshall University Research Corporation Methods for stem cell production and therapy
AU2014338555B2 (en) 2013-10-24 2019-10-10 Fondazione Telethon Method
US9410143B1 (en) 2014-06-10 2016-08-09 Endonovo Therapeutics, Inc. Biological molecules produced by electromagnetically stimulating living mammalian cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US6962698B1 (en) * 1998-02-17 2005-11-08 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US6485963B1 (en) * 2000-06-02 2002-11-26 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof
EP1337625B1 (de) * 2000-11-29 2004-07-14 Albert Scheller Stammzellen, verfahren zu deren expansion in vitro sowie deren verwendung
US20040136969A1 (en) * 2002-10-02 2004-07-15 New York University Adult bone marrow derived stem cells
DE10362002B4 (de) * 2003-06-23 2006-10-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Adulte pluripotente Stammzellen
WO2005007799A2 (en) * 2003-07-17 2005-01-27 Gamida-Cell Ltd. Methods for ex-vivo expanding stem/progenitor cells
US20050084962A1 (en) * 2003-08-20 2005-04-21 Bruce Simon Methods of treatment using electromagnetic field stimulated stem cells
US20080057042A1 (en) * 2005-01-27 2008-03-06 Donnie Rudd Method of providing readily available cellular material derived from cord blood, and a composition thereof
US20080075700A1 (en) * 2006-02-27 2008-03-27 Wolf David A Method and composition for treating diabetes
US20080050348A1 (en) * 2006-02-27 2008-02-28 Donnie Rudd Method and composition for repairing heart tissue

Also Published As

Publication number Publication date
WO2006093858A3 (en) 2006-11-30
KR20070111533A (ko) 2007-11-21
WO2006093858A2 (en) 2006-09-08
CN101188941A (zh) 2008-05-28
US20060193838A1 (en) 2006-08-31
EP1855535A2 (en) 2007-11-21
MX2007010531A (es) 2007-11-08
JP2008531695A (ja) 2008-08-14
CA2599275A1 (en) 2006-09-08
IL185555A0 (en) 2009-02-11
BRPI0607882A2 (pt) 2009-11-24
EP1855535A4 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
EA200701390A1 (ru) Способ получения легкодоступного клеточного материала из пуповинной крови и композиция на его основе
EA200701600A1 (ru) Способ получения лёгкодоступного клеточного материала из периферической крови и композиция на его основе
EA200701599A1 (ru) Способ и композиция для восстановления сердечной ткани
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
EA200870019A1 (ru) Лактамовые соединения и способы их применения
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
EA200802213A1 (ru) Способы лечения заболеваний крови
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA200800812A1 (ru) Композиции антитела против cd3
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
NO20083011L (no) Modulatorer av muskarine receptorer
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
TW200608966A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
RS20080246A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
EA200701826A1 (ru) Способ и композиция для лечения диабета
EA201071293A1 (ru) Композиция для укладки волос